Drugs / PF-07853578
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05890105 | Jun → Dec 2023 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07853578 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05890105 ↗ |
| Route | Oral | “PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.” NCT05890105 ↗ |